6B11-OCIK

N/A

Report date: 2025/06/12 15:43:09

Base Information

Drug Name6B11-OCIK
Drug Alias Name6B11抗独特型微抗体负载DC和细胞因子诱导的自体卵巢癌杀伤细胞（北京纬晓生物）Autologous ovarian cancer cell toxic T lymphocyte6B11-OCIK
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Ovarian Epithelial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Weixiao Biotechnology Development Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesImmunotech Applied Science Ltd
Inactive CompaniesBeijing Weixiao Biotechnology Development Co LtdPeking University People'S Hospital
Active IndicationsCarcinoma, Ovarian Epithelial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A